Journal of Neural Transmission

, Volume 64, Issue 3–4, pp 187–198 | Cite as

Sub-chronic administration of (−)-3-PPP and central dopamine receptor sensitivity changes

  • St. Hjorth
  • D. Clark
  • K. Svensson
  • A. Carlsson
  • O. Thorberg
Original Papers


The effects of sub-chronic treatment with (−)-3-PPP (8 mg/kg, s.c., b.i.d. for 21 days), a dopaminergic agent with mixed agonist/antagonist properties, were investigated by means of behavioural andin vivo biochemical methods. There was no change in basal locomotor activity and central dopamine (DA) synthesis after 24 hours withdrawal. A slight, though significant reduction of the locomotor suppressive effect and of the DA synthesis-stimulating effect of acute (−)-3-PPP challenge doses of 0.125 and 1.0 mg/kg (s.c.), respectively, were demonstrated in (−)-3-PPP-pretreated as compared to vehicle-pretreated rats. No change in either action was evident after acute challenge with 8.0 mg/kg (s.c.) of the drug. The plasma levels of (−)-3-PPP were virtually unchanged by pretreatment with active drug. The findings are discussed in terms of a modest down- and up-regulation of DA autoreceptors and postsynaptic receptors, respectively, induced by the subchronic (−)-3-PPP treatment.

Key words

(−)-3-PPP([−]-3-[3-hydroxyphenyl]-N-n-propylpiperidine) subchronic treatment rats dopamine receptors sensitivity changes 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahlenius, S., Hillegaart, V., Magnusson, O., Lundström, J.: Behavioral and biochemical effects of subchronic treatment with (−)-3-(3-hydroxyphenyl)-N-n-propylpiperidine in the rat: Dopamine receptor sensitivity and tolerance. J. Neural Transm.60, 103–113 (1984).PubMedGoogle Scholar
  2. Antelman, S., Chiodo, L.: Dopamine autoreceptor subsensitivity: a mechanism common to the treatment of depression and the induction of amphetamine psychosis. Biol. Psychiat.16, 717–727 (1981).PubMedGoogle Scholar
  3. Ariens, E. J.: Receptors: the materialization of a concept. Pharmaceut. Weekbl. Sci. Ed.5, 121–128 (1983).Google Scholar
  4. Arnt, J., Bøgesø, K. P., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacol.81, 199–207 (1983 a).Google Scholar
  5. Arnt, J., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur. J. Pharmacol.86, 185–198 (1983 b).Google Scholar
  6. Carlsson, A.: Dopamine receptor agonists: Intrinsic activity vs. state of the receptor. J. Neural Transm.57, 309–315 (1983).PubMedGoogle Scholar
  7. Carlsson, A., Lindqvist, M.: Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brainin vivo. J. Pharm. Pharmacol.25, 437–440 (1973).PubMedGoogle Scholar
  8. Clark, D., Hjorth, S., Carlsson, A.: (+)- and (−)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis. Eur. J. Pharmacol.106, 185–189 (1984).PubMedGoogle Scholar
  9. Clark, D., Hjorth, S., Carlsson, A.: Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J. Neural Transm.62, 1–52 (1985 a).PubMedGoogle Scholar
  10. Clark, D., Hjorth, S., Carlsson, A.: Dopamine receptor agonists: Mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J. Neural Transm.62, 171–207 (1985 b).PubMedGoogle Scholar
  11. Ezrin-Waters, C., Seeman, P.: L-Dopa reversal of hyperdopaminergic behaviour. Life Sci.22, 1027–1032 (1978).PubMedGoogle Scholar
  12. Hjorth, S.: On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. (Thesis) Acta Physiol. Scand.118, suppl. 517, 1–52 (1983).Google Scholar
  13. Hjorth, S., Carlsson, A., Clark, D., Svensson, K., Wikström, H., Sanchez, D., Lindberg, P., Hacksell, U., Arvidsson, L.-E., Johansson, A., Nilsson, J. L. G.: Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacol.81, 89–99 (1983).Google Scholar
  14. Hjorth, S., Carlsson, A., Wikström, H., Lindberg, P., Sanchez, D., Hacksell, U., Arvidsson, L.-E., Svensson, U., Nilsson, J. L. G.: 3-PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci.28, 1225–1238 (1981).PubMedGoogle Scholar
  15. Jackson, D., Carlsson, A., Hjorth, S., Lindberg, P.: A behavioural study of the changes in the CNS of mice after sub-chronic treatment with the selective dopamine-autoreceptor agonist 3-PPP (dl-3-[3-hydroxyphenyl]N-n-propylpiperidine. J. Neural Transm.53, 233–245 (1982).PubMedGoogle Scholar
  16. Kinon, B. J., Merson, D., Kane, J. M.: Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioural hypersensitivity in the rat. Psychopharmacol.84, 347–350 (1984).Google Scholar
  17. List, S. L., Seeman, P.: Dopamine agonists reverse the elevated3H-neuroleptic binding in neuroleptic pretreated rats. Life Sci.24, 1447–1452 (1979).PubMedGoogle Scholar
  18. Martin, G. E., Haubrich, D. R., Williams, M.: Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99. Eur. J. Pharmacol.76, 15–23 (1981).PubMedGoogle Scholar
  19. Møller Nielsen, I., Christensen, A. V., Hyttel, J.: Adaptational phenomena in neuroleptic treatment. In: Adv. Biochem. Psychopharmacol., Vol. 19 (Roberts, P. J. et al., eds.), pp. 267–274. New York: Raven Press. 1978.Google Scholar
  20. Rebec, G. V., Lee, E. H.: Differential subsensitivity of dopaminergic and neostriatal neurons to apomorphine with long-term treatment. Brain Res.250, 188–192 (1982).PubMedGoogle Scholar
  21. Schneider, M. B., Murrin, L. C., Pfeiffer, R. F., Deupree, J. D.: Dopamine receptors: Effects of chronic L-Dopa and Bromocriptine treatment an animal model of Parkinson's disease. Clin. Neuropharmacol.7, 247–257 (1984).PubMedGoogle Scholar
  22. Schwartz, J. C., Costentin, J., Martres, M. P., Protais, P., Baudry, M.: Modulation of receptor mechanisms in the CNS: hyper- and hyposensitivity to catecholamines. Neuropharmacol.17, 665–685 (1978).Google Scholar
  23. Shum, A., Sole, M. J., van Loon, G. R.: Simultaneous measurements of 5-hydroxytryptophan and L-dihydroxyphenylalanine by high-performance liquid chromatography with electrochemical detection. Measurement of serotonin and catecholamine turnover in discrete brain regions. J. Chromatogr.228, 123–130 (1982).PubMedGoogle Scholar
  24. Tarsy, D., Baldessarini, R. J.: Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacol.13, 927–940 (1974).Google Scholar
  25. Walters, J. R., Bunney, B. S., Roth, R. H.: Piribedil and apomorphine: pre- and postsynaptic effects on dopamine synthesis and neuronal activity. Adv. Neurol.9, 273–284 (1975).PubMedGoogle Scholar
  26. White, F. J., Wang, R. Y.: Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic d-amphetamine treatment. Brain Res.309, 283–292 (1984).PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1986

Authors and Affiliations

  • St. Hjorth
    • 1
  • D. Clark
    • 3
  • K. Svensson
    • 1
  • A. Carlsson
    • 1
  • O. Thorberg
    • 2
  1. 1.Department of PharmacologyUniversity of GöteborgSweden
  2. 2.Research and Development Laboratories, Organic Chem. SectionAB AstraSödertäljeSweden
  3. 3.Lab. Neurophysiol., Ctr. for Cell BiologySinai Hospital of DetroitDetroitUSA

Personalised recommendations